Loading patent…
AssigneeOpko Renal, LLC
InventorsCharles W. Bishop, Keith H. Crawford, Eric J. Messner
Estimating the term…
Methods and compositions for treating 25-hydroxyvitamin D insufficiency and deficiency in a patient are described herein. The method includes orally administering to the patient a delayed, sustained release formulation including a first ingredient selected from the group consisting of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3, or it includes gradually administering to the patient a sterile intravenous formulation including a first ingredient selected from the group consisting of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3.
A method of treating 25-hydroxyvitamin D insufficiency or deficiency in a patient comprising orally administering to the patient a sustained release formulation of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 in combination with one or more calcium salts, bisphosphonates, calcimimetics, nicotinic acid, iron, phosphate binders, glycemic control agents, hypertension control agents, and antineoplastic agents.
A sustained release oral dosage formulation of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 in combination with one or more calcium salts, bisphosphonates, calcimimetics, nicotinic acid, iron, phosphate binders, cholecalciferol, ergocalciferol, active Vitamin D sterols, glycemic and hypertension control agents, and antineoplastic agents.
A sustained release oral dosage formulation of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 dispersed within a matrix and encased with a coating material.
A sustained release oral dosage formulation of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 dispersed within a matrix and comprising a permeable overcoating.
A sustained release oral dosage formulation of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 dispersed within a matrix which is solid at body temperature.
-51. (canceled)
A controlled release oral formulation comprising 25-hydroxyvitamin D3 and a pharmaceutical-grade matrix excipient.
A controlled release formulation comprising 25-hydroxyvitamin D3 dispersed within a matrix wherein the matrix comprises a mixture of rate controlling constituents and excipients.
A capsule comprising 25-hydroxyvitamin D3 and a controlled release excipient.
A pharmaceutical composition comprising 25-hydroxyvitamin D3 and a controlled release delivery system.
Dependencies are inferred from the claim text.